ABT-199 is a BH3 mimetic that inhibits Bcl-2 but does not affect Bcl-xl. ABT-199 exhibits anticancer chemotherapeutic activity, inducing Bim-mediated apoptosis in chronic lymphocytic leukemia (CLL) cells. ABT-199 also induces cell death and inhibits tumor growth in acute myelogenous leukemia (AML) models in vitro, ex vivo, and in vivo. ABT-199 is currently under examination as a potential treatment for CLL.
Uniformity of Dosage Units
Allschoolabs
Uniformity of Dosage Units is a specialised analytical laboratory service that assesses whether individual dosage units contain sufficiently consis...



































